SCHEMBL6608440

SCHEMBL6608440

Fc1ccc(-c2c[nH]c(S)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.41
RAB9A P51151 3/20 0.40
ALDH1A1 P00352 2/20 0.40
ALOX5 P09917 1/20 0.40
KDM5B Q9UGL1 1/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CDC7 O00311 1/20 0.36
PIM1 P11309 1/20 0.36
GSK3B P49841 1/20 0.36
HIPK2 Q9H2X6 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
PDGFRB P09619 1/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 2/20 0.36
AR P10275 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6177597 0.80 METAP2 (0.41) RAB9AALDH1A1POLBSMN1; SMN2KDM4E
SCHEMBL6609394 0.80 PDGFRB (0.41) RAB9AALOX5KDM5BSMN1; SMN2PDGFRB
SCHEMBL2215451 0.79 MEN1 (0.44) MAPK1RAB9AALDH1A1POLBSMN1; SMN2
Hydrochloric Acid SCHEMBL6165643 0.78 KMT2A (0.41) RAB9AALDH1A1POLBSMN1; SMN2KDM4E
SCHEMBL15029205 0.78 MAPK1 (0.42) MAPK1RAB9AALDH1A1ALOX5KDM5B
SCHEMBL4874412 0.78 LMNA (0.40) MAPK1RAB9AALDH1A1KDM5BSMN1; SMN2
SCHEMBL14404777 0.76 MAPK1 (0.41) MAPK1RAB9AALDH1A1ALOX5KDM5B
SCHEMBL8356431 0.76 MAPK1 (0.41) MAPK1RAB9AALDH1A1ALOX5KDM5B
SCHEMBL2419681 0.76 ALDH1A1 (0.48) MAPK1RAB9AALDH1A1ALOX5KDM5B
SCHEMBL15823275 0.76 RAD51 (0.43) MAPK1RAB9AALDH1A1ALOX5KDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170313661-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER SYNOVO GMBH (DE) 2017-11-02 US disclosed
EP-1373217-A1 2-MERCAPTO-4,5-DIARYLIMIDAZOLE DERIVATIVES AND THE USE THEREOF AS CYCLOOXYGENASE INHIBITORS Beiersdorf AG (DE) 2004-01-02 EP disclosed
WO-2002076951-A1 2-MERCAPTO-4,5-DIARYLIMIDAZOLE DERIVATIVES AND THE USE THEREOF AS CYCLOOXYGENASE INHIBITORS BEIERSDORF AG (DE) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313661-A1 KINASE MODULATORS FOR THE TREATMENT OF CANCER MAP3K10, MAP3K12, MAP3K20 MAPK1 160/4885RAB9A 2039/4885ALDH1A1 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.